`
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`In re Patent Application of:
`Katsuhiko Maruo
`
`Application No.: 13/378,448
`
`Confirmation No.: 1084
`
`Filed: December 15, 2011
`
`Art Unit: 1631
`
`For: BLOOD SUGAR VALUE ESTllVIATION
`
`Examiner: J. M. Sims
`
`APPARATUS
`
`INFORMATION DISCLOSURE STATEMENT {IDS}
`
`MS Amendment
`
`Commissioner for Patents
`
`PO. Box 1450
`
`Alexandria, VA 22313—1450
`
`Dear Sir/Madam:
`
`Pursuant to 37 C.F.R. § 1.56, 1.97 and 1.98, the attention of the Patent and Trademark
`
`Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully
`
`requested that the information be expressly considered during the prosecution of this application,
`
`and that the references be made of record therein and appear among the “References Cited” on any
`
`patent to issue therefrom.
`
`This Information Disclosure Statement is filed more than three months after the US
`
`filing date, OR more than three months after the date of entry of the national stage of a PCT
`
`application, AND after the mailing date of the first Office Action on the merits, Whichever occurs
`
`first, but before the mailing date of any of a Final Office Action, a Notice of Allowance (37 C.F.R.
`
`§ 1.97(c)) or an action that otherwise closes prosecution in the application.
`
`AM 496624081
`
`
`
`Application No.: 13/378,448
`
`2
`
`Docket N0.: 89884(316697)
`
`Ihereby certify, pursuant to 37 C.F.R. § 1.97(e)(1), that each item of information
`
`contained in this Information Disclosure Statement was first cited in any communication from a
`
`foreign patent office in a counterpart foreign application not more than three months prior to the
`
`filing of this Information Disclosure Statement.
`
`In accordance with 37 C.F.R. § 1.98(a)(2)(ii), Applicant has not submitted copies of US.
`
`patents and US. patent applications. Applicant submits herewith copies of foreign patents and non—
`
`patent literature in accordance with 37 C.F.R. § 1.98(a)(2).
`
`In accordance with 37 C.F.R. § l.97(g), the filing of this Information Disclosure
`
`Statement shall not be construed to mean that a search has been made or that no other material
`
`information as defined in 37 C.F.R. § 1.56(a) exists. In accordance with 37 C.F.R. § l.97(h), the
`
`filing of this Information Disclosure Statement shall not be construed to be an admission that any
`
`patent, publication or other information referred to therein is “prior art” for this invention unless
`
`specifically designated as such.
`
`It is submitted that the Information Disclosure Statement is in compliance with 37 C.F.R.
`
`§ 1.98 and the Examiner is respectfully requested to consider the listed references.
`
`The Director is hereby authorized to charge any deficiency in the fees filed, asserted to
`
`be filed or which should have been filed herewith (or with any paper hereafter filed in this
`
`application by this firm) to our Deposit Account No. 04—1105, under Order No. 89884(316697).
`
`Dated: May 4, 2015
`
`Respectfully submitted,
`
`/James E. Armstrong, IV/
`Electronic signature:
`James E. Armstrong, IV
`Registration No.: 42,266
`James M. Acheson, Jr.
`
`Registration No.: 45,585
`LOCKE LORD LLP
`
`P.O. Box 55874
`
`Boston, Massachusetts 02205
`
`(202) 478-7375
`
`Attorneys/Agents For Applicant
`
`AM 496624081
`
`